What caused the significant decrease in net earnings for the third quarter of 2019 compared to the prior year?

The substantial decrease in net earnings for the third quarter of 2019, from $3.934 billion to $1.753 billion, was primarily driven by a significant "Other (income) expense, net" of $4.214 billion. This expense was largely attributed to an "agreement in principle to settle opioid litigation."

How did sales perform across Johnson & Johnson's business segments in the third quarter of 2019?

Worldwide sales increased by 1.9% to $20.7 billion. The Pharmaceutical segment showed strong operational growth of 6.4%, led by Oncology and Immunology. The Medical Devices segment experienced an operational decline of 2.0%, impacted by divestitures, though Vision and Interventional Solutions performed well. The Consumer segment saw modest operational growth of 3.3%, with Beauty and OTC franchises leading the way.

What is the status of Johnson & Johnson's legal matters, particularly the opioid litigation?

The company has reached an "agreement in principle to settle opioid litigation," which resulted in a significant charge in the third quarter of 2019. This settlement is subject to finalization and various conditions. The company is also involved in numerous other product liability claims, patent disputes, and government investigations across its segments, as detailed in Note 11. While the company believes it has defenses, the ultimate outcome of these matters, including the opioid litigation, could materially affect results of operations and cash flows.

What impact did acquisitions and divestitures have on the company's results?

Acquisitions, such as Auris Health and Dr. Ci:Labo, contributed to sales growth in certain segments. However, divestitures, including the Advanced Sterilization Products (ASP) business and LifeScan, negatively impacted the Medical Devices segment's reported sales and operational growth. The net impact of acquisitions and divestitures on worldwide operational sales growth was negative in both the third quarter and nine months ended September 29, 2019.

JNJ 10-Q Quarterly Report Q3 FY2019 — Revenue, Net Income, EPS

Summary

Johnson & Johnson (JNJ) reported net earnings of $1.753 billion for the third quarter of 2019, down significantly from $3.934 billion in the same period of 2018. This decline was largely driven by a significant "Other (income) expense, net" of $4.214 billion in the current quarter, primarily attributed to an "agreement in principle to settle opioid litigation." For the nine months ended September 29, 2019, net earnings were $11.109 billion, compared to $12.255 billion in the prior year. Despite the earnings dip, worldwide sales for the third quarter of 2019 increased by 1.9% to $20.7 billion, with operational growth of 3.2%, driven by strong performance in the Pharmaceutical segment, particularly in Oncology and Immunology. The Medical Devices segment saw a slight operational decline, impacted by divestitures. Investors should note the significant legal and restructuring charges impacting profitability, while recognizing the underlying operational sales growth and continued strength in key pharmaceutical product lines.

Financial Highlights

53 data points

Beta

Revenue

$20.73B

0.7% Gross Margin

Net Income

$1.75B

0.1% Net Margin

EPS (Diluted)

$0.66

Total Assets

$155.52B

Cash & Equivalents

$16.25B

Free Cash Flow

$6.78B

Financial Statements

Beta

Revenue	$20.73B
Cost of Revenue	$6.87B
Gross Profit	$13.86B
SG&A Expenses	$5.37B
Interest Expense	$48.00M
Net Income	$1.75B
EPS (Basic)	$0.67
EPS (Diluted)	$0.66
Shares Outstanding (Basic)	2.64B
Shares Outstanding (Diluted)	2.67B

Key Highlights

1Third quarter 2019 net earnings of $1.753 billion, a decrease from $3.934 billion in Q3 2018, largely due to significant opioid litigation settlement accruals.
2Worldwide sales increased by 1.9% to $20.7 billion in Q3 2019, with operational growth of 3.2% driven by the Pharmaceutical segment.
3Pharmaceutical segment sales grew 5.1% operationally to $10.9 billion in Q3 2019, with strong performance in Oncology (DARZALEX®, IMBRUVICA®) and Immunology (STELARA®, TREMFYA®).
4Medical Devices segment sales decreased by 3.1% to $6.4 billion in Q3 2019, impacted by divestitures of LifeScan and ASP, although key areas like Interventional Solutions and Vision showed operational growth.
5Consumer segment sales increased by 1.6% to $3.5 billion in Q3 2019, with positive operational growth in Beauty and OTC franchises.
6The company recorded significant "Other (income) expense, net" of $4.214 billion in Q3 2019, largely due to an "agreement in principle to settle opioid litigation."
7Diluted EPS decreased to $0.66 in Q3 2019 from $1.44 in Q3 2018, reflecting the impact of litigation charges and other factors.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Sep 29, 2019

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions